1. Home
  2. FTS vs UTHR Comparison

FTS vs UTHR Comparison

Compare FTS & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fortis Inc.

FTS

Fortis Inc.

N/A

Current Price

$58.08

Market Cap

29.2B

Sector

Utilities

ML Signal

N/A

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

N/A

Current Price

$532.81

Market Cap

23.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FTS
UTHR
Founded
1885
1996
Country
Canada
United States
Employees
9900
1400
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.2B
23.9B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
FTS
UTHR
Price
$58.08
$532.81
Analyst Decision
Hold
Buy
Analyst Count
1
13
Target Price
$72.00
$524.62
AVG Volume (30 Days)
677.1K
404.1K
Earning Date
01-01-0001
05-28-2026
Dividend Yield
3.16%
N/A
EPS Growth
N/A
13.07
EPS
N/A
27.86
Revenue
N/A
$1,483,300,000.00
Revenue This Year
$13.48
$7.77
Revenue Next Year
$6.05
$11.11
P/E Ratio
$22.72
$19.54
Revenue Growth
N/A
2.38
52 Week Low
$43.28
$266.98
52 Week High
$58.23
$548.12

Technical Indicators

Market Signals
Indicator
FTS
UTHR
Relative Strength Index (RSI) 66.88 61.99
Support Level $50.65 $463.64
Resistance Level N/A N/A
Average True Range (ATR) 0.87 19.18
MACD -0.07 5.07
Stochastic Oscillator 88.98 85.06

Price Performance

Historical Comparison
FTS
UTHR

About FTS Fortis Inc.

Fortis owns and operates eight utility transmission and distribution subsidiaries in Canada and the United States, serving roughly 3.5 million electricity and gas customers. The company has smaller stakes in electricity generation and several Caribbean utilities. Subsidiary ITC operates electric transmission in seven US states, with more than 16,000 miles of high-voltage transmission lines in operation.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: